ZYBERNO
Stock Report
Updated Aug 29, 2026

Moderna, Inc. (MRNA)

Healthcare • NASDAQ

$134.40
Moderna Inc. is an American biotechnology company headquartered in Cambridge, Massachusetts, that pioneered messenger RNA (mRNA) therapeutics and vaccine development. The company co-developed the Spikevax mRNA COVID-19 vaccine and has an extensive pipeline of mRNA-based vaccines and therapeutics for infectious diseases, cancer, cardiovascular disease, and rare genetic diseases, leveraging its proprietary mRNA platform technology.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
43.0/100
WEAK BUSINESS
Moderna, Inc. (MRNA) scores 43/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-39.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.20x)
Operating Margin (Operational Efficiency):CRITICAL (-245.2%)
Return on Capital (Capital Efficiency):CRITICAL (-43.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Moderna, Inc. (MRNA) stock report — Zyberno Score 43/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, MRNA generated -$1.60B in Owner Earnings. Capital was deployed as follows: $137.00M invested in capital expenditures. Reinvestment rate: 0.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:134.40
Market Cap:$53.49B

Valuation Multiples (3)

P/B Ratio:7.91x
P/S Ratio:39.51x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$52.52B

Price Action & Momentum (3)

Momentum Percentile:96 / 100
% of 52-Week High:76.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-26.9%
Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-0.3%

Margin Analysis (3)

Operating Margin Ttm:-245.2%
Net Margin Ttm:-232.7%
Ebitda Margin:-228.3%

TTM Performance (3)

Gross Margin Ttm:-19.6%
Operating Margin Ttm:-245.2%
Net Margin Ttm:-232.7%

Yield Metrics (2)

Earnings Yield:-$5.94
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:58.7%
Latest Earnings Filed:2026-07-31

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):56.2%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):23.4%
Operating Cash Flow Growth Rate (Linear):26.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.29x
Quick Ratio:2.18x
Cash Ratio:0.68x

Leverage Analysis (3)

Debt To Equity Ttm:0.20x
Debt-to-Equity Ratio:0.20x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:3,281,000,000.00
Cash And Cash Equivalents:1,723,000,000.00
Long Term Debt:$591.00M
Net Debt:-$969.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.35B
Linear Growth: 56.2%
📊 Click to view full MRNA Revenue analysis & methodology →
Cost Of Revenue Ttm:$1.71B

Profitability Breakdown (2)

Gross profit TTM: -$265.00M
Linear Growth: -3.7%
📊 Click to view full MRNA Gross Profit analysis & methodology →
-$3.32B

Bottom Line Performance (3)

Net income TTM: -$3.15B
Linear Growth: -50.0%
📊 Click to view full MRNA Net Income analysis & methodology →
Income Before Tax:-$3.09B
Ebitda Ttm:-3,091,000,000.00

Operating Expenses (5)

Operating Expenses:5,548,000,000.00
R And D Expense:2,876,000,000.00
Sga Expense:965,000,000.00
Income Tax Expense:$64.00M
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:1,983.4%
Sga To Revenue Percentage:665.5%
Ebitda Margin:-228.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$10.96B
Current Assets:$5.82B
Ppe Net:0.00
Goodwill:52,000,000.00
Intangible Assets:$109.00M

Liability Structure (4)

Total Liabilities:4,200,000,000.00
Current Liabilities:2,534,000,000.00
Long Term Debt:$591.00M
Short Term Debt:$163.00M

Equity & Capital (3)

Equity:$6.76B
Retained Earnings:$5.10B
Common Stock:1,600,000,000.00

Working Capital Items (3)

Accounts Receivable:120,000,000.00
Inventory:280,000,000.00
Accounts Payable:1,909,000,000.00

Special Items (2)

Contract Liabilities:442,000,000.00
Stock Based Compensation:120,000,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$1.47B
Linear Growth: 26.9%
Free cash flow TTM: -$1.60B
Linear Growth: 23.4%
📊 Click to view full MRNA Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$76.00M
Capital Expenditures Ttm:137,000,000.00

Financing Activities (3)

Financing Cash Flow:$17.00M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:229,000,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.98
Eps diluted TTM: -$7.98
Linear Growth: -50.0%
📊 Click to view full MRNA EPS analysis & methodology →
Earnings Per Share Ttm:-$7.92

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.40
Operating Cash Flow Per Share:-$4.71

Book Value & Capital (2)

Book Value Per Share:$16.99
Cash Per Share:4.33

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.12x
Working Capital Turnover Ttm:0.41x

Receivables Management (2)

Receivables Turnover Ttm:11.28x
Days Sales Outstanding Ttm:32.35

Inventory Management (2)

Inventory Turnover Ttm:6.10x
Days Inventory Outstanding Ttm:59.87

Payables & Cash Cycle (2)

Days Payable Outstanding:408.19
Cash Conversion Cycle:-315.97
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$1.60B

Damodaran Growth Analysis (2)

Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-0.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):56.2%
Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):23.4%
Operating Cash Flow Growth Rate (Linear):26.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-3.7%
Book Value Growth Rate (Linear):-20.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:MRNA
Company Name:Moderna, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:398.00M
Shares Outstanding Basic:398.00M
Shares Outstanding Diluted:398.00M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 02:29:35 UTC
Data Timestamp:2026-08-29T02:29:35.550878
Scroll to Top